← Eichor
Study identifier: NCT06752668 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Condition: Narcolepsy Type 1 · Narcolepsy Type 2 · Idiopathic Hypersomnia  ·  Sponsor: Centessa Pharmaceuticals (UK) Limited

PhasePhase 2
Planned participants248
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. * IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton (also known as ORX750) is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can…

This description comes directly from the study's public registry record.

Talk to the study team

Centessa Pharmaceuticals  ·  +1 617-468-5770  ·  CRYSTAL-1@centessa.com

Always discuss trial participation with your own doctor first.

Locations (37)

Auburn, AlabamaAuburn, Alabama, United StatesRecruiting
Chandler, ArizonaChandler, Arizona, United StatesRecruiting
Scottsdale, ArizonaScottsdale, Arizona, United StatesRecruiting
Long Beach, CaliforniaLong Beach, California, United StatesRecruiting
Santa Ana, CaliforniaSanta Ana, California, United StatesRecruiting
Brandon, FloridaBrandon, Florida, United StatesRecruiting
Miami, FloridaMiami, Florida, United StatesRecruiting
Miami, FloridaMiami, Florida, United StatesRecruiting
Orlando, FLOrlando, Florida, United StatesRecruiting
Winter Park, FloridaWinter Park, Florida, United StatesRecruiting
Atlanta, GeorgiaAtlanta, Georgia, United StatesRecruiting
Atlanta, GeorgiaAtlanta, Georgia, United StatesRecruiting

+ 25 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06752668